Loading...

NMRA NEUMORA THERAPEUTICS INC Management Changes 8-K Filing

NMR

NMR

NEUMORA THERAPEUTICS INC

(NMRA)

2025 8-K

Financial Results Announcement

Investor Presentation

Investor Presentation

Positive Study Results

Stock Conversion Notice

Financial Results Update

Phase 1 Study Initiated

Positive Drug Data

Financial Statements

Delisting due to Non-Compli...

Financial Statements

Financial Results

Leadership Changes

Leadership Changes

Investor Presentation

Q3 Financial Results

External Links:

Neumora Therapeutics announced significant leadership changes effective February 14, 2025, including Paul L. Berns becoming CEO and several executives transitioning to new roles, along with salary increases and stock options for key personnel.

AI Assistant

NEUMORA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.